PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Both companies show declining cash positions (-13.40% vs AVXL's -9.40%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Cash + STI yoy 1.25-1.5x AVXL's -9.40%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
1.25-1.5x AVXL's -9.35%. Bruce Berkowitz checks if strong current asset growth is used effectively.
8.92%
Below half AVXL's -19.89%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
Below half of AVXL's -19.89%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
1.25-1.5x AVXL's -9.35%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
25.71%
Less than half of AVXL's -4.06%. David Dodd sees a more disciplined AP approach or lower volume.
-32.96%
Above 1.5x AVXL's -3.32%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
Similar yoy changes to AVXL's -54.54%. Walter Schloss finds parallel near-term liability trends.
-28.78%
Above 1.5x AVXL's -4.82%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Above 1.5x AVXL's -4.82%. Michael Burry sees a potential leverage warning sign.
1.95%
Less than half of AVXL's 8.15%. David Dodd sees fewer share issuances vs. competitor.
-3.92%
0.5-0.75x AVXL's -6.25%. Martin Whitman is wary of weaker retention or lower profitability.
-19.50%
1.25-1.5x AVXL's -14.12%. Martin Whitman is wary of bigger swings in AOCI.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
0.75-0.9x AVXL's -10.29%. Bill Ackman wonders if competitor is growing equity faster.
-12.20%
1.25-1.5x AVXL's -9.35%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Above 1.5x AVXL's -3.38%. Michael Burry sees a major jump. Investigate leverage rationale.
13.20%
1.25-1.5x AVXL's 9.44%. Martin Whitman is wary of heavier net leverage vs. competitor.